Histamine H1 Receptor Antagonists

Histamine-1 Receptor Antagonist

Rhinitis, Allergic, Perennial

Urticaria

<section class="Section" data-sectioncode="34089-3"><a name="s31"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Cetirizine hydrochloride, the active component of QUZYTTIR, is a selective histamine-1 (H<span class="Sub">1</span>) receptor antagonist.  The chemical name is (±) –[2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperzinyl] ethoxy]acetic acid, dihydrochloride.  Cetirizine hydrochloride is a racemic compound with an empirical formula of C<span class="Sub">21</span>H<span class="Sub">25</span>ClN<span class="Sub">2</span>O<span class="Sub">3</span>•2HCl.  The molecular weight is 461.82 and the chemical structure is shown below:</p><p><a name="f01"></a><img alt="Chemical Structure
" src="quz00-0000-01.jpg"/></p><p>Cetirizine hydrochloride is a white, crystalline powder and is water soluble.  QUZYTTIR is a sterile, clear, colorless, non-pyrogenic, isotonic solution for intravenous injection.  Each mL of QUZYTTIR injection contains 10 mg cetirizine hydrochloride (equivalent to cetirizine 8.42 mg) and 6.5 mg sodium chloride, USP to adjust solution tonicity, in water for injection, USP.  QUZYTTIR is supplied in 2 mL size amber glass vials for single use.  Each 2 mL size amber glass vial contains 1 mL drug solution with 10 mg cetirizine hydrochloride (10 mg/mL).  QUZYTTIR's pH is maintained between 4.5 to 6.5 with sodium hydroxide and/or hydrochloric acid as needed. The osmolality of QUZYTTIR injection is between 255 to 340 mOsmol.</p></section>

QUZYTTIR

cetirizine hydrochloride

cetirizine

1 ML cetirizine hydrochloride 10 MG/ML Injection

Quzyttir

1 ML cetirizine hydrochloride 10 MG/ML Injection [Quzyttir]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Submit MSL Request

Pharmacy List 

How To Order Quzyttir 

Reimbursement Guide 

Reimbursement Coding Options for Hospital Outpatient and ASC Services

Coverage Authorization Request

Coverage Authorization Appeals

TeraSera SupportSource Quzyttir Enrollment Form 

Enroll in Patient Savings Program

Reimbursement Information

Other HCP Resources

About Quzyttir

Doctor Discussion Guide

Instructions for Use: Urticaria